Applications: | Immunodepletion/Immunocompetition |
Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: | Phospho-ErbB 2 Blocking Peptide is synthetically produced from the 1100-1150 sequence and is suitable for use in western blot applications. |
Storage Instruction: | Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
Gene Symbol: | ERBB2 |
Gene ID: | 2064 |
Uniprot ID: | ERBB2_HUMAN |
Immunogen Region: | 1100-1150 |
Immunogen: | Phoshporylated synthetic peptide taken within amino acid region 1100-1150 on human HER-2 protein |
Tissue Specificity | Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth. |
Post Translational Modifications | Autophosphorylated. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit (Probable). Ligand-binding increases phosphorylation on tyrosine residues. Signaling via SEMA4C promotes phosphorylation at Tyr-1248. Dephosphorylated by PTPN12. |
Function | Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization. In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A.the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth. |
Peptide Name | Receptor Tyrosine-Protein Kinase Erbb-2Metastatic Lymph Node Gene 19 ProteinMln 19Proto-Oncogene NeuProto-Oncogene C-Erbb-2Tyrosine Kinase-Type Cell Surface Receptor Her2P185erbb2Cd Antigen Cd340 |
Database Links | Reactome: R-HSA-1227986Reactome: R-HSA-1250196Reactome: R-HSA-1251932Reactome: R-HSA-1257604Reactome: R-HSA-1306955Reactome: R-HSA-1358803Reactome: R-HSA-1963640Reactome: R-HSA-1963642Reactome: R-HSA-2219530Reactome: R-HSA-416572Reactome: R-HSA-5673001Reactome: R-HSA-6785631Reactome: R-HSA-6811558Reactome: R-HSA-8847993Reactome: R-HSA-8863795Reactome: R-HSA-8866910Reactome: R-HSA-9634285Reactome: R-HSA-9652282Reactome: R-HSA-9664565Reactome: R-HSA-9665233Reactome: R-HSA-9665244Reactome: R-HSA-9665245Reactome: R-HSA-9665246Reactome: R-HSA-9665247Reactome: R-HSA-9665249Reactome: R-HSA-9665250Reactome: R-HSA-9665251Reactome: R-HSA-9665348Reactome: R-HSA-9665686Reactome: R-HSA-9665737 |
Cellular Localisation | Cell MembraneSingle-Pass Type I Membrane ProteinCell ProjectionRuffle MembraneInternalized From The Cell Membrane In Response To Egf StimulationIsoform 1: Cell MembraneEarly EndosomeCytoplasmPerinuclear RegionNucleusTranslocation To The Nucleus Requires EndocytosisProbably Endosomal Sorting And Is Mediated By Importin Beta-1/Kpnb1Also Detected In Vps35-Positive Endosome-To-Tgn Retrograde VesiclesIsoform 2: CytoplasmIsoform 3: Cytoplasm |
Alternative Peptide Names | Receptor Tyrosine-Protein Kinase Erbb-2 proteinMetastatic Lymph Node Gene 19 Protein proteinMln 19 proteinProto-Oncogene Neu proteinProto-Oncogene C-Erbb-2 proteinTyrosine Kinase-Type Cell Surface Receptor Her2 proteinP185erbb2 proteinCd Antigen Cd340 proteinERBB2 proteinHER2 proteinMLN19 proteinNEU proteinNGL protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance